RE:RE:RE:RE:RE:RE:Theratechnologies Confirms Issuance Of U.S. Patent Covering Oh great point!.. it's a biosimilar right? So a generic version couldn't be substituted without consulting the prescriber first (unless it has "interchangeable" status which is very rarely given)? I really hope we get that right..
qwerty22 wrote: I meant to write both work against skinny labels.
qwerty22 wrote:
It's classed as a biologic. The original indication is so different to the NASH indication. Both seem to work against biologics.
Its interesting they only mention tesamorelin, when we first heard about this it was to all GHRH analogs. Is that still true?
Great 1st PR, can we expect more?
Spartrap wrote: Great news indeed.. Unfortunately the patent alone won't protect TH from "skinny labeling" practices by generic drug makers, which will likely end up eating a significant part of the market opportunity, but it's giving a lot more credence to the whole NAFLD/NASH project. Hopefully, the F8 formula will be so much easier that patients will ask for "dispense as written" mentions on the script.
palinc2000 wrote: This is great news,,,,,,We may have a good week